450 related articles for article (PubMed ID: 19372954)
1. Treatment interruption as a tool to measure changes in immunologic response to HIV-1.
Kutzler MA; Jacobson JM
Curr Opin HIV AIDS; 2008 Mar; 3(2):131-5. PubMed ID: 19372954
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. Monitoring clinical trials of therapeutic vaccines in HIV infection: role of treatment interruption.
Lederman MM; Penn-Nicholson A; Stone SF; Sieg SF; Rodriguez B
Curr Opin HIV AIDS; 2007 Jan; 2(1):56-61. PubMed ID: 19372866
[TBL] [Abstract][Full Text] [Related]
4. Preparation for antiretroviral interruption by boosting the immune system.
Yves L
Curr Opin HIV AIDS; 2008 Mar; 3(2):118-23. PubMed ID: 19372952
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic immunization strategies for HIV infection.
Heath SL; Kilby JM
Curr Opin HIV AIDS; 2006 Jan; 1(1):74-81. PubMed ID: 19372788
[TBL] [Abstract][Full Text] [Related]
7. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.
Jacobson JM; Pat Bucy R; Spritzler J; Saag MS; Eron JJ; Coombs RW; Wang R; Fox L; Johnson VA; Cu-Uvin S; Cohn SE; Mildvan D; O'Neill D; Janik J; Purdue L; O'Connor DK; Vita CD; Frank I;
J Infect Dis; 2006 Sep; 194(5):623-32. PubMed ID: 16897661
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection.
Oxenius A; Price DA; Günthard HF; Dawson SJ; Fagard C; Perrin L; Fischer M; Weber R; Plana M; García F; Hirschel B; McLean A; Phillips RE
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13747-52. PubMed ID: 12370434
[TBL] [Abstract][Full Text] [Related]
9. Immune modulators and treatment interruption.
García F; Fumero E; Gatell JM
Curr Opin HIV AIDS; 2008 Mar; 3(2):124-30. PubMed ID: 19372953
[TBL] [Abstract][Full Text] [Related]
10. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
[TBL] [Abstract][Full Text] [Related]
11. Treatment interruption to boost specific HIV immunity in acute infection.
Kaufmann DE; Walker BD
Curr Opin HIV AIDS; 2007 Jan; 2(1):21-5. PubMed ID: 19372861
[TBL] [Abstract][Full Text] [Related]
12. Treatment interruption for convenience, cost cutting and toxicity sparing.
Nüesch R; Hirschel B
Curr Opin HIV AIDS; 2007 Jan; 2(1):31-8. PubMed ID: 19372863
[TBL] [Abstract][Full Text] [Related]
13. Immune reconstitution in HIV-1-infected patients.
Imami N; Hardy G; Pires A; Burton C; Pido-Lopez J; Mela C; Gotch F
Curr Opin Investig Drugs; 2002 Aug; 3(8):1138-45. PubMed ID: 12211404
[TBL] [Abstract][Full Text] [Related]
14. Strategies to decrease viral load rebound, and prevent loss of CD4 and onset of resistance during structured treatment interruptions.
Foli A; Maserati R; Barasolo G; Castelli F; Tomasoni L; Migliorino M; Maggiolo F; Pan A; Paolucci S; Scudeller L; Tinelli C; D'Aquila R; Lisziewicz J; Lori F
Antivir Ther; 2004 Feb; 9(1):123-32. PubMed ID: 15040544
[TBL] [Abstract][Full Text] [Related]
15. Computer simulation of structured treatment interruption for HIV infection.
Ferreira J; Hernandez-Vargas EA; Middleton RH
Comput Methods Programs Biomed; 2011 Nov; 104(2):50-61. PubMed ID: 21899913
[TBL] [Abstract][Full Text] [Related]
16. Virological rebound and its consequences during treatment interruption.
van Lunzen J; Hoffmann C
Curr Opin HIV AIDS; 2007 Jan; 2(1):1-5. PubMed ID: 19372858
[TBL] [Abstract][Full Text] [Related]
17. Treatment interruption in HIV therapy: a SMART strategy?
Jülg B; Goebel FD
Infection; 2006 Jun; 34(3):186-8. PubMed ID: 16804667
[TBL] [Abstract][Full Text] [Related]
18. Combining antiretroviral drugs and immune therapies: an approach to achieve clinical benefit after treatment interruption.
Lisziewicz J
Curr Opin HIV AIDS; 2008 Mar; 3(2):104-11. PubMed ID: 19372950
[TBL] [Abstract][Full Text] [Related]
19. Favorable outcome of ex-vivo purging of monocytes after the reintroduction of treatment after interruption in patients infected with multidrug resistant HIV-1.
Hasson H; Mantelli B; Biswas P; Malnati M; Gianotti N; Vecchi A; Nozza S; Cernuschi M; Boeri E; Clerici M; Lazzarin A; Beretta A
J Med Virol; 2007 Nov; 79(11):1640-9. PubMed ID: 17854028
[TBL] [Abstract][Full Text] [Related]
20. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection.
Cardiello PG; Hassink E; Ananworanich J; Srasuebkul P; Samor T; Mahanontharit A; Ruxrungtham K; Hirschel B; Lange J; Phanuphak P; Cooper DA
Clin Infect Dis; 2005 Feb; 40(4):594-600. PubMed ID: 15712083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
